127 related articles for article (PubMed ID: 30145821)
21. Pharmacological preconditioning by TERT inhibitor BIBR1532 confers neuronal ischemic tolerance through TERT-mediated transcriptional reprogramming.
Xie X; Li M; Zhou M; Chow SF; Tsang CK
J Neurochem; 2021 Nov; 159(4):690-709. PubMed ID: 34532857
[TBL] [Abstract][Full Text] [Related]
22. Down regulation of human telomerase reverse transcriptase (hTERT) expression by BIBR1532 in human glioblastoma LN18 cells.
Lavanya C; Venkataswamy MM; Sibin MK; Srinivas Bharath MM; Chetan GK
Cytotechnology; 2018 Aug; 70(4):1143-1154. PubMed ID: 29546682
[TBL] [Abstract][Full Text] [Related]
23. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
24. BIBR1532 Affects Endometrial Cell Proliferation, Migration, and Invasion in Endometriosis via Telomerase Inhibition and MAPK Signaling.
Zhao X; Luo D; Liu T; Zhang H; Xie Y; Kong W
Gynecol Obstet Invest; 2023; 88(4):226-239. PubMed ID: 37429261
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of telomerase recruitment and cancer cell death.
Nakashima M; Nandakumar J; Sullivan KD; Espinosa JM; Cech TR
J Biol Chem; 2013 Nov; 288(46):33171-80. PubMed ID: 24097987
[TBL] [Abstract][Full Text] [Related]
26. TERT inhibition leads to reduction of IL-6 expression induced by palmitic acid and interferes with the protective effects of tibolone in an astrocytic cell model.
González-Giraldo Y; Garzón-Benitez AV; Forero DA; Barreto GE
J Neuroendocrinol; 2019 Aug; 31(8):e12768. PubMed ID: 31278797
[TBL] [Abstract][Full Text] [Related]
27. Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.
Celeghin A; Giunco S; Freguja R; Zangrossi M; Nalio S; Dolcetti R; De Rossi A
Cell Death Dis; 2016 Dec; 7(12):e2562. PubMed ID: 28032863
[TBL] [Abstract][Full Text] [Related]
28. Screening of telomerase inhibitors.
Kleideiter E; Piotrowska K; Klotz U
Methods Mol Biol; 2007; 405():167-80. PubMed ID: 18369824
[TBL] [Abstract][Full Text] [Related]
29. Combination of resveratrol and BIBR1532 inhibits proliferation of colon cancer cells by repressing expression of LncRNAs.
Cesmeli S; Goker Bagca B; Caglar HO; Ozates NP; Gunduz C; Biray Avci C
Med Oncol; 2021 Nov; 39(1):12. PubMed ID: 34779924
[TBL] [Abstract][Full Text] [Related]
30. Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors.
Piotrowska K; Kleideiter E; Mürdter TE; Taetz S; Baldes C; Schaefer U; Lehr CM; Klotz U
Lab Invest; 2005 Dec; 85(12):1565-9. PubMed ID: 16170334
[TBL] [Abstract][Full Text] [Related]
31. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
Rankin AM; Faller DV; Spanjaard RA
Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
[TBL] [Abstract][Full Text] [Related]
32. The Small Molecule BIBR1532 Exerts Potential Anti-cancer Activities in Preclinical Models of Feline Oral Squamous Cell Carcinoma Through Inhibition of Telomerase Activity and Down-Regulation of TERT.
Altamura G; Degli Uberti B; Galiero G; De Luca G; Power K; Licenziato L; Maiolino P; Borzacchiello G
Front Vet Sci; 2020; 7():620776. PubMed ID: 33553285
[TBL] [Abstract][Full Text] [Related]
33. BIBR1532 inhibits proliferation and enhances apoptosis in multiple myeloma cells by reducing telomerase activity.
Zhang Y; Yang X; Zhou H; Yao G; Zhou L; Qian C
PeerJ; 2023; 11():e16404. PubMed ID: 37953768
[TBL] [Abstract][Full Text] [Related]
34. BIBR 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: therapeutic potential for APL.
Bashash D; Ghaffari SH; Zaker F; Kazerani M; Hezave K; Hassani S; Rostami M; Alimoghaddam K; Ghavamzadeh A
Anticancer Agents Med Chem; 2013 Sep; 13(7):1115-25. PubMed ID: 23293885
[TBL] [Abstract][Full Text] [Related]
35. Telomerase inhibitor MST-312 induces apoptosis of multiple myeloma cells and down-regulation of anti-apoptotic, proliferative and inflammatory genes.
Ameri Z; Ghiasi S; Farsinejad A; Hassanshahi G; Ehsan M; Fatemi A
Life Sci; 2019 Jul; 228():66-71. PubMed ID: 31029779
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
37. Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532).
El Daly H; Martens UM
Methods Mol Biol; 2007; 405():47-60. PubMed ID: 18369817
[TBL] [Abstract][Full Text] [Related]
38. Investigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cells.
Doğan F; Özateş NP; Bağca BG; Abbaszadeh Z; Söğütlü F; Gasımlı R; Gündüz C; Biray Avcı Ç
J Cell Biochem; 2019 Feb; 120(2):1282-1293. PubMed ID: 30368861
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG.
Berletch JB; Liu C; Love WK; Andrews LG; Katiyar SK; Tollefsbol TO
J Cell Biochem; 2008 Feb; 103(2):509-19. PubMed ID: 17570133
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer.
Kala R; Shah HN; Martin SL; Tollefsbol TO
BMC Cancer; 2015 Oct; 15():672. PubMed ID: 26459286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
